Nachrichten zur ASTRAZENECA DL-,25 SP.ADR Aktie

Pharma Stock Roundup: JNJ to Buy Shockwave Medical, Other Pipeline & Regulatory News

J&J (JNJ) is set to buy Shockwave Medical (SWAV). FDA approves AstraZenecas (AZN) Enhertu for metastatic HER2-positive solid tumors.…

AstraZenecas (AZN) Fasenra Gets FDA Nod for Asthma in Kids

The FDA approves AstraZenecas (AZN) Fasenra as an add-on maintenance treatment for patients with severe asthma aged six to 11…

AstraZeneca Shareholders Vote in Favor of £19 Million CEO Pay

AstraZeneca Plc shareholders backed a pay increase for Pascal Soriot, who is already the highest paid chief executive officer of…

AstraZeneca shareholders approve 2024 pay policy in boost to CEO Soriot By Reuters

AstraZeneca shareholders approve 2024 pay policy in boost to CEO Soriot…

Result of AGM

11 April 2024 1730 BST Results of Annual General Meeting held on 11 April 2024 AstraZeneca PLC announced the results of the…

AstraZeneca to boost annual dividend by 7%

…

AstraZeneca unveils dividend hike ahead of CEO pay vote at AGM By Reuters

AstraZeneca unveils dividend hike ahead of CEO pay vote at AGM…

AstraZeneca increases 2024 dividend by 7%

11 April 2024 AstraZeneca increases 2024 dividend by 7% AstraZeneca announced today that the Board intends to increase the annualised dividend for…

Ihre wichtigsten Termine: Heute im Blick: AstraZeneca, Frosta, Givaudan, VAT, Gerresheimer, Adecco & Emmi

AstraZeneca pay debate exposes disparity in US-UK corporate values

Tomorrow’s shareholder vote on AstraZeneca PLC (LSE:AZN) boss Pascal Soriot’s compensation represents a microcosm of the broader debate around executive...…

AstraZeneca pay debate exposes disparity in US-UK corporate values

Tomorrow’s shareholder vote on AstraZeneca PLC (LSE:AZN) boss Pascal Soriot’s compensation represents a microcosm of the broader debate around executive...…

BARCLAYS stuft ASTRAZENECA auf Overweight

LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat die Einstufung für Astrazeneca auf "Overweight" mit einem Kursziel von 12500…

Krank nach Corona-Impfung - Astrazeneca zu Auskunft verurteilt

BAMBERG (dpa-AFX) - Im Prozess um einen mutmaßlichen Corona-Impfschaden hat eine Frau aus Oberfranken einen Teilerfolg gegen den Hersteller Astrazeneca…

Enhertu approved in US for HER2+ solid tumours

08 April 2024 Enhertu approved in the US as first tumour-agnostic HER2-directed therapy for previously treated patients with metastatic HER2-positive solid tumours Based on…

AstraZenecas (AZN) Enhertu Gets FDA Nod for Solid Tumors

FDA approves AstraZeneca (AZN) and partner Daiichi Sankyos Enhertu for HER2-expressing metastatic cancers based on data from three phase II…

US FDA approves Daiichi, AstraZeneca drug for treatment of solid tumors By Reuters

US FDA approves Daiichi, AstraZeneca drug for treatment of solid tumors…

Astrazeneca: Wichtiges Medikament erreicht Ziele in Lungenkrebsstudie

CAMBRIDGE (dpa-AFX) - Der Pharmakonzern Astrazeneca hat in einer abschließenden klinischen Studie (Phase-III) mit Lungenkrebs-Patienten einen Erfolg erzielt. Das…

Imfinzi improved OS & PFS in limited-stage SCLC

05 April 2024 Imfinzi significantly improved overall survival and progression-free survival for patients with limited-stage small cell lung cancer in ADRIATIC Phase…

Pharma Stock Roundup: AZN Voydeya Gets FDA Nod, MRK KRAS Inhibitor Enters Phase III

FDA approves AstraZenecas (AZN) Voydeya (danicopan) in the United States as add on therapy to its other C5 inhibitors. Merck…

AstraZenecas (AZN) Imfinzi Improves Survival in SCLC Study

AstraZenecas (AZN) Imfinzi improves overall survival and progression-free survival for patients with limited-stage small cell lung cancer in the phase…

Total Voting Rights

2 April 2024 15:00 BST Transparency Directive Voting rights and capital The following notification is made in accordance with the UK Financial Conduct…

FDA accepts Dato-DXd BLA for breast cancer

2 April 2024 Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated metastatic HR-positive, HER2-negative breast…

AstraZenecas (AZN) Rare Blood Disorder Drug Gets FDA Nod

FDA approves AstraZenecas (AZN) Voydeya as an add-on to therapy to Ultomiris or Soliris for treating extravascular hemolysis in adult…

AstraZeneca (AZN) Dato-DXd Breast Cancer BLA Gets FDA Acceptance

AstraZenecas (AZN) BLA is seeking approval of Dato-DXd for previously treated metastatic HR-positive, HER2-negative breast cancer.…

AstraZeneca gets FDA approval for PNH drug Voydeya

…

DEUTSCHE BANK RESEARCH stuft ASTRAZENECA auf Sell

FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Astrazeneca auf "Sell" mit einem Kursziel von 9500 Pence…

[Latest] Global PARP Inhibitors Market Size/Share Worth USD 23.5 Billion by 2032 at a 12.1% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)

[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global…

BioStock: Spago Nanomedical’s CEO: “huge commercial opportunities are unfolding”

Last week we saw the USD 2 billion buyout of Fusion Pharmaceuticals by AstraZeneca to accelerate the development of next-generation…

AstraZeneca CEO Soriot on Pharmaceuticals in China

AstraZeneca CEO Pascal Soriot discusses the drugmaker’s business strategy in China, the US “BIOSECURE Act,” and future deals and partnerships…

Astra, Pfizer Boost China Bets Despite US Drive to Decouple

The chief executive officers of AstraZeneca Plc and Pfizer Inc. pledged to support expansion of China’s biopharmaceutical industry, even as…

AstraZenecas (AZN) Ultomiris Gets FDA Nod for New Indication

FDA approves AstraZenecas (AZN) Ultomiris for AQP4 Ab+ NMOSD, making it the first and only long-acting C5 complement inhibitor approved…

UBS stuft ASTRAZENECA auf Sell

ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat die Einstufung für Astrazeneca auf "Sell" mit einem Kursziel von 9900…

Pharma Stock Roundup: AZN to Buy FUSN, PFE to Sell Stake in HLN & Other Updates

AstraZeneca (AZN) is set to acquire Fusion Therapeutics (FUSN). Pfizer (PFE) plans to sell some shares of Haleon to lower…

AstraZeneca (AZN) to Buy Fusion Pharmaceuticals for $2.4B

AstraZeneca (AZN) has offered to acquire Fusion for $21.00 per share in cash plus a contingent value (CV) payment of…

Fusion (FUSN) Up 99% on $2.4B Buyout Offer From AstraZeneca

AstraZeneca (AZN) is set to acquire Fusion Biopharma (FUSN) for $21 per share in cash, along with a contingent value…

What AstraZeneca Is Getting Through The Acquisition Of Fusion Pharmaceuticals

…

Fusion Pharmaceuticals Stock Soars. It’s Being Acquired by AstraZeneca in $2.4 Billion Deal.

…

Biotech Nearly Doubles After Scoring $2 Billion AstraZeneca Takeover

The company is working on radiopharmaceuticals treatments for cancer.…

AstraZeneca: Der Pharma-Riese bleibt in Sachen M&A sehr aktiv - Aktienanalyse

Kulmbach (www.aktiencheck.de) - AstraZeneca-Aktienanalyse von "Der Aktionär": Michel Doepke vom Anlegermagazin "Der Aktionär" nimmt in einer aktuellen Aktienanalyse die Aktie des…

AstraZeneca is paying $2.4bn for Fusion Pharmaceuticals - but actually is it getting

AstraZeneca PLC (LSE:AZN) is acquiring Canadas Fusion Pharmaceuticals for $2.4 billion, in a bid to effectively keep up with Joneses…

AstraZeneca bets on new cancer treatments with $2 billion Fusion Pharma purchase

The deal is AstraZenecas second this month after it agreed last week to buy Amolyt Pharma for $1.05 billion to…

AstraZeneca will buy Fusion Pharmaceuticals for ~$2B

…

AstraZeneca to Buy Fusion Pharma for Up to $2.4 Billion

AstraZeneca Plc agreed to buy Fusion Pharmaceuticals Inc. for as much as $2.4 billion as it seeks to transform cancer…

AstraZeneca to buy Fusion Pharma for $2 billion in cash By Reuters

AstraZeneca to buy Fusion Pharma for $2 billion in cash…

AstraZeneca to acquire Fusion

19 March 2024 AstraZeneca to acquire Fusion to accelerate the development of next-generation radioconjugates to treat cancer Includes actinium-based clinical-stage radioconjugate targeting PSMA…

AstraZeneca caps inhaler costs at $35 for eligible US patients By Investing.com

AstraZeneca caps inhaler costs at $35 for eligible US patients…

AstraZeneca to cap US out-of-pocket costs for inhalers at $35 per month By Reuters

AstraZeneca to cap US out-of-pocket costs for inhalers at $35 per month…

Kommunen fordern "Atempause" bei Flüchtlingen - TE-Wecker am 18. März 2024

Kommunen fordern "Atempause" bei Flüchtlingen ++ EU schließt 7,4-Milliarden-Flüchtingsdeal mit Ägypten ++ Teilurteil in Corona-Prozess gegen AstraZeneca erwartet ++ neue…

Pharma Stock Roundup: AZNs New Acquisition, FDA Updates for NVO & LLY and More

AstraZeneca (AZN) is set to buy a private rare disease drugmaker. FDA delays decision on Lillys (LLY) donanemab and approves…

AstraZeneca: Milliardenschwerer Deal verkündet - Aktienanalyse

Kulmbach (www.aktiencheck.de) - AstraZeneca-Aktienanalyse von "Der Aktionär": Michel Doepke vom Anlegermagazin "Der Aktionär" nimmt in einer aktuellen Aktienanalyse die Aktie des…

dpa-AFX ProFeed